The city of Boston, Massachusetts, currently has 465 active clinical trials seeking participants for Cancer research studies.
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
NCT03645928
Recruiting
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL LN-144 (Lifileucel)/LN-145 in combination with checkpoint inhibitors or TIL LN-144 (Lifileucel)/LN-145/LN-145-S1 as a single agent therapy.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/04/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
Register for Updates
ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas
NCT03922555
Recruiting
this research study is evaluating the highest dose of ASTX727 that can be administered safely to recurrent/progressive non-enhancing IDH mutant gliomas patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +2 locations
Conditions: Neurological Cancer
Register for Updates
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
NCT04039230
Recruiting
This research is studying the effect of Antibody-Drug Conjugate Sacituzumab Govitecan in Combination with the Poly (Adenosine Diphosphate \[ADP\]-Ribose) Polymerase (PARP) Inhibitor Talazoparib in Patients with Metastatic Triple-Negative Breast Cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/28/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +1 locations
Conditions: Breast Cancer
Register for Updates
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer
NCT03285412
Recruiting
This research study is studying a drug as a possible treatment for ER-positive Breast Cancer The drug involved in this study is: -Ribociclib
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/28/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Breast Cancer
Register for Updates
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
NCT03803553
Recruiting
This research study is comparing two standard of care treatment options based on blood test results for participants who have metastatic colon cancer. The names of the potential treatments involved in this study are: * Active surveillance * FOLFIRI treatment * Nivolumab treatment * Encorafenib/Binimetinib/Cetuximab treatment * Trastuzumab + Pertuzumab
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Metastatic Colon Cancer, Stage III Colon Cancer
Register for Updates
Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress
NCT04541654
Recruiting
The purpose of this research study is to learn more about variants in the TP53 gene both associated with Li-Fraumeni Syndrome (LFS), a hereditary cancer risk condition, and TP53 variants found in the blood for other reasons (e.g. ACE/CHIP and mosaicism).
Gender:
ALL
Ages:
All
Trial Updated:
03/18/2024
Locations: Boston Children's Hospital, Boston, Massachusetts +2 locations
Conditions: Li-Fraumeni Syndrome, TP53 Gene Mutation, Hereditary Cancer Syndrome, Clonal Hematopoiesis, Mosaicism
Register for Updates
Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer
NCT02290834
Recruiting
This research study evaluates the effect of chemotherapy on cognition (thinking) and the brain in people with breast cancer.
Gender:
FEMALE
Ages:
60 years and above
Trial Updated:
03/18/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Impaired Cognition, Chemo-brain, Breast Cancer
Register for Updates
Sacituzumab Govitecan In TNBC
NCT04230109
Recruiting
This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC) The names of the study drugs involved in this study is: * Sacituzumab govitecan (SG) * Pembrolizumab (combination therapy with SG)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts +2 locations
Conditions: Invasive Breast Cancer, Triple Negative Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, HER2-negative Breast Cancer
Register for Updates
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)
NCT04443348
Recruiting
This research trial is studying a combination of neoadjuvant radiotherapy (RT), immunotherapy (pembrolizumab) and chemotherapy for lymph node-positive, triple negative (TN) or hormone receptor positive/HER2-negative breast cancer. The names of the study interventions involved in this study are: * Radiation Therapy (RT) * Immunotherapy: Pembrolizumab (MK-3475) * Chemotherapies: * Paclitaxel * Doxorubicin (also called Adriamycin) * Cyclophosphamide * Carboplatin (optional, and in TN onl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph Node(s)
Register for Updates
Immune and Genomic Markers in ALK+ NSCLC
NCT04881916
Recruiting
The purpose of this research study is to obtain and study clinical history, and tissue and saliva specimens if available from participants with Anaplastic Lymphoma Kinase-ALK+ Non-Small Lung Cancer(NSCLC)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Anaplastic Lymphoma Kinase Gene Translocation, Non-Small Cell Lung Cancer
Register for Updates
Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation
NCT06146920
Recruiting
The goal of this prospective study to investigate the use of circulating tumor DNA (ctDNA) to guide end of therapy decisions in patients with melanoma or non-small-cell lung cancer. The main question it aims to answer is: • Do patients with metastatic melanoma or non-small-cell lung cancer, who have received at least 12 months of immune checkpoint inhibition (monotherapy or in combination) with evidence of disease response/control on imaging and have no evidence of circulating tumor DNA, have... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Melanoma, Non-small Cell Lung Cancer
Register for Updates
Cryoablation+Ipilimumab+Nivolumab in Melanoma
NCT05779423
Recruiting
The aim of this study is to find out whether the combination of two approved drugs, ipilimumab and nivolumab, in combination with cryoablation are safe and effective for participants who have an unresectable melanoma that is resistant, or is growing, after receiving immunotherapy with a PD-1 inhibitor. The names of the study interventions involved in this study are: * Cryoablation (an interventional radiology procedure that freezes part of a tumor) * Ipilimumab (an immunotherapy) * Nivolumab (... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Metastatic Melanoma, Skin Cancer
Register for Updates